News Medical

Centhaquine drug improves outcomes, reduces death rate in patients with severe blood or fluid loss

Centhaquine, a new medication to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate when added to standard of care, compared to standard care ...
Business Wire

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...
Business Insider

Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

FORT WAYNE, Ind., Nov. 24, 2020 /PRNewswire/ -- Vivacelle Bio, Inc. today announces the Department of Defense awarded $5.3 million (USD) dollars for the clinical trial of VBI-S, an intravenously ...
Nature

Hemodynamic Responses to Central Hypovolemia and Blood Loss

Central hypovolemia, frequently resulting from blood loss or shifts in vascular volume, presents significant challenges in clinical and emergency settings. The body’s response involves a cascade of ...
Nature

Impact of Norepinephrine and Fluid on Cerebral Oxygenation in Experimental Hemorrhagic Shock

Hypovolemia is the most common cause of circulatory failure in children (1). When inadequate tissue perfusion is not recognized and treated rapidly, critical tissue hypoxia may develop, leading to ...
KTLA

Vivacelle Bio's VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and ...